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Summary
 
Dendritic cells (DCs) express several receptors for the Fc portion of immunoglobulin (Ig)G
(Fc
 
g
 
R), which mediate internalization of antigen–IgG complexes (immune complexes, ICs)
and promote efficient major histocompatibility complex (MHC) class II–restricted antigen pre-
sentation. We now show that Fc
 
g
 
Rs have two additional specific attributes in murine DCs: the
induction of DC maturation and the promotion of efficient MHC class I–restricted presenta-
tion of peptides from exogenous, IgG-complexed antigens. Both Fc
 
g
 
R functions require the
Fc
 
g
 
R-associated 
 
g
 
 chain. Fc
 
g
 
R-mediated MHC class I–restricted antigen presentation is ex-
tremely sensitive and specific to immature DCs. It requires proteasomal degradation and is de-
pendent on functional peptide transporter associated with antigen processing, TAP1-TAP2. By
promoting DC maturation and presentation on both MHC class I and II molecules, ICs should
 
efficiently sensitize DCs for priming of both CD4
 
1
 
 helper and CD8
 
1
 
 cytotoxic T lymphocytes
in vivo.
Key words: Fc receptors • dendritic cells • antigen presentation • immune complexes • 
cross-priming
ajor histocompatibility complex (MHC) class I mol-
ecules are generally complexed exclusively with pep-
tides derived from cytosolic antigens (1). However, this pic-
 
ture is too restrictive to explain the priming of naive CD8
 
1
 
T cells by bone marrow (BM)
 
1
 
-derived APCs (2): APCs
also internalize exogenous antigens for processing and pre-
sentation on MHC class I molecules. The induction of CTL
response due to exogenous antigen transfer was first exam-
ined in response to minor histocompatibility antigens, and
was referred to as cross-priming (3). Recent results suggest
that DCs may play a critical role in this process (4).
Indeed, dendritic cells (DCs) are the most potent APCs
for inducing differentiation of naive CD4
 
1
 
 and CD8
 
1
 
 T
cells into helper and cytotoxic T cells, respectively, and for
initiating primary and secondary immune responses (5, 6).
To prime T cell responses, DCs require several separate
signals. The first is provided by antigens themselves, which
are processed into peptides and loaded intracellularly onto
MHC molecules. Efficient T cell priming also requires a
cell activation signal, delivered by either inflammatory cy-
tokines (TNF-
 
a
 
 or IL-1) or bacterial components (such as
LPS). This signal induces expression of MHC and T cell
costimulatory molecules at the DC surface and causes mi-
gration from peripheral tissues to secondary lymphoid or-
gans, where T cell priming occurs. Cognate CD4
 
1
 
 T cell
help is also required for efficient CD8
 
1
 
 T cell priming,
with antigen recognition by both CD4
 
1
 
 and CD8
 
1
 
 T cells
 
1
 
Abbreviations used in this paper:
 
 BM-DC, bone marrow–derived DC;
CHX, cycloheximide; DC, dendritic cell; Fc
 
g
 
R-ct
 
g
 
, chimeric receptor
composed of the lumenal and transmembrane domains of Fc
 
g
 
RII and the
cytoplasmic tail of the 
 
g
 
 chain; HEL, hen egg lysozyme; IC, immune
complex; ITAM, immunoreceptor tyrosine-based activation motif; LLnL,
 
aldehyde 
 
N
 
-acetyl-Leu-
 
l
 
-Leu-
 
l
 
-norleucinal; OVA-IC, OVA-contain-
ing IC; PTK, protein tyrosine kinase; TAP, transporter associated with
antigen processing; wt, wild-type.
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on the same DC (7–10). Therefore, this DC requires the
simultaneous presentation of peptides from exogenous anti-
gens on both MHC class I and II molecules.
Presentation of peptides derived from exogenous antigens
on MHC class I molecules may occur through two different
pathways (11). First, internalized antigens may exit endocytic
compartments and, once in the cytosol, be processed by the
proteasome into peptides which then reach the conventional
transporter associated with antigen processing (TAP)1/2-
dependent MHC class I antigen presentation pathway. Alter-
natively, internalized antigens may be processed in endocytic
compartments, generating peptides which associate to preex-
isting MHC class I molecules, either in endosomes or at the
cell surface after peptide regurgitation.
Regardless of the pathway, cross-priming in vitro after
fluid phase antigen internalization is generally very inefficient,
since it requires very high antigen concentrations—in the
mg/ml range (11). Antigen coupling to or mixing with latex
beads forces internalization by phagocytosis and strongly en-
hances the efficiency of MHC class I–restricted antigen pre-
sentation in macrophages or DCs (12, 13). Phagocytosis of
bacteria (14, 15) or of apoptotic cells (4) also results in effi-
cient MHC class I–restricted antigen presentation in macro-
phages and/or DCs. Thus, the pathway by which antigens are
internalized appears to influence the efficiency of presentation
on both MHC class I and II molecules.
In the case of MHC class II–restricted presentation, a
major breakthrough came from the observation that anti-
gens internalized through specific membrane receptors are
more efficiently presented to CD4
 
1
 
 T cells than they are
after fluid phase internalization (16). Fc
 
g
 
Rs, which bind
antigen–IgG complexes (immune complexes, ICs [17]),
represent a privileged antigen internalization route for effi-
cient MHC class II–restricted antigen presentation in DCs
(18). Human DCs express several types of Fc
 
g
 
Rs, includ-
ing type I (Fc
 
g
 
RI, CD64 [19]) and type II (Fc
 
g
 
RII, CD32
[18]). Fc
 
g
 
R expression by murine DCs has not been fully
examined. Importantly, in addition to IC internalization,
Fc
 
g
 
RI and Fc
 
g
 
RIII trigger cell activation (17) through the
associated 
 
g
 
 chain, which bears a motif called immunore-
ceptor tyrosine-based activation motif (ITAM), also re-
quired for IC internalization (20, 21).
Here, we examined the role of Fc
 
g
 
Rs in DC activation
and in MHC class I–restricted presentation of peptides de-
rived from internalized IgG-complexed antigens. We found
that Fc
 
g
 
R engagement in DCs triggers maturation and in-
duces efficient MHC class I and II–restricted antigen pre-
sentation. These results suggest the existence of unknown
connections between humoral and cytotoxic components of
immune responses.
 
Materials and Methods
 
Mice.
 
g
 
 chain
 
2
 
/
 
2
 
 mice were obtained on a B6 
 
3
 
 129 back-
ground (22) and TAP
 
2
 
/
 
2
 
 mice from Centre National de la Re-
cherche Scientifique (Orleans, France). TAP
 
2
 
/
 
2
 
 mice were on a
B6 
 
3 
 
129 background (23).
 
DCs and Culture Medium.
 
Immature DCs were prepared as
 
described (24). C57BL/6 and 
 
g
 
 chain
 
2
 
/
 
2
 
 BM cells were incu-
bated 3 wk in IMDM (Sigma Chemical Co.) containing 10%
heat-inactivated FBS (GIBCO BRL), 100 IU/ml penicillin, 100
mg/ml streptomycin, 2 mM 
 
l
 
-glutamine (Sigma), and 50 mM
2-
 
b
 
ME with 30% conditioned medium from GM-CSF–producing
NIH/3T3 cells (R1 medium). D1 long-term cultured cell line is
an H-2
 
b
 
 splenic DC cell line described by Winzler et al. (24) and
was also cultured in the same medium with 30% R1 medium.
The cells expressed MHC class I and II molecules, CD40, CD80,
CD86, and 24G.2
 
1
 
 Fc
 
g
 
R, but not Gr1. The surface expression
of all of these molecules, except Fc
 
g
 
Rs, was increased after LPS
treatment for 24 h, indicating effective DC maturation.
 
Antibodies, Cell Surface Staining, and Immunofluorescence.
 
The
following antibodies were purchased from PharMingen: CD80/
B7.1 (1G10), CD40 (HM40-3), CD86/B7.2 (GL1), CD107a/
Lamp-1. Before labeling experiments, FcR blocking was per-
formed by incubating cells with 2.4G2 supernatant. Staining was
carried out according to standard techniques, and flow cytometry
analysis was performed with a FACScan
 
®
 
 (using CellQuest soft-
ware; Becton Dickinson). For intracellular immunofluorescence,
cells were fixed for 20 min in 3% paraformaldehyde and then
permeabilized for 30 min in PBS containing 1% saponin, 5%
BSA, and then stained in PBS containing 1% saponin, 5% BSA.
 
Antigen Presentation Assay.
 
OVA batches from different com-
panies were screened for the absence of presentation to B3Z cells
with fixed cells. The selected batch (from Worthington) did not
induce DC activation by immunofluorescence and flow cytome-
try. Presentation of OVA epitope 257–264 on K
 
b
 
 was detected
using the T cell hybridoma B3Z, which carries a 
 
b
 
-galactosidase
construct driven by NF-AT elements from the IL-2 promoter
(25). For antigen presentation assays, DCs were exposed to OVA,
at the concentration and for the periods of time specified, in the
presence of the T cell hybridoma B3Z. After exposure to OVA,
cells were washed with PBS, and a colorimetric assay using
ONPG (Sigma Chemical Co.) as a substrate was used to detect
LacZ activity in B3Z lysates. Where indicated, the following in-
hibitors were included in the antigen presentation assays.
MHC class II–restricted response to ovalbumin was detected
using two T cell hybridomas, BO97.10, specific for OVA 323–
339 on I-A
 
b
 
 (26) on DCs, and 54.8, specific for the same peptide
presented on I-A
 
d
 
. 20 h after antigen pulsing, DCs were fixed
with glutaraldehyde 0.001%, and BO97.10 cells were added for
24 h. After 24 h, 50 ml of supernatant was harvested and the IL-2
production by BO97.10 was measured with [
 
3
 
H]thymidine in-
corporation by IL-2–dependent CTL L2 cell line.
Lactacystin and the peptide aldehyde 
 
N
 
-acetyl-Leu-
 
l
 
-Leu-
 
l
 
-norleucinal (LLnL) were stored in DMSO as 1 and 2.5 mM stock
solutions, respectively, and they were diluted in culture media for
use. 5 
 
3 
 
10
 
4
 
 D1 cells/well were incubated with the inhibitors for
1 h before antigen pulsing and during the antigen pulse. OVA-
containing ICs (OVA-ICs) were prepared by incubation at 37
 
8
 
C,
15 min of soluble OVA at a final concentration of 0.4 and 20 
 
m
 
g/
ml of anti-OVA IgGs purified from rabbit sera (Sigma Chemical
Co.). As a control for inhibitor toxicity, we used the OVA 257–
264 peptide at a final concentration of 10 ng/ml. After a chase of
12 h, D1 cells were fixed with glutaraldehyde 0.001%, overlaid
with 5 
 
3 
 
10
 
4
 
 B3Z cells/well, and incubated for 24 h.
 
Activation Induced by ICs.
 
5 
 
3 
 
10
 
4
 
 D1 cells/well were incu-
bated with soluble OVA alone or in the presence of hen egg
lysozyme (HEL)-ICs (at final concentrations: HEL 30 
 
m
 
g/ml,
and mAbs anti-HEL, HyHEL5, and 5253C7, 15 
 
m
 
g/ml each
[27]) and were overlaid with 5 
 
3 
 
10
 
4
 
 B3Z cells/well and incu-
bated for 24 h. 
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Figure 1. (A) FcgR expression in D1 cells. FcgRII and FcgRIII a chain molecules were immuno-
precipitated with 2.4G2 mAb, and FcgRIIb1, b2, and FcgRIII were revealed by Western blot with (1)
or without (2) deglycosylation. (B) ICs induce DC maturation. D1 cells were incubated for 24 h alone
(dotted line) or in the presence of LPS (solid line) or OVA-ICs (0.4 mg/ml of OVA and 20 mg/ml of
rabbit anti-OVA IgGs; bold line). The cells were then stained for MHC class II (Y3P), CD40 (HM40-3),
and CD86/B7.2 (GL1) and analyzed by FACscan.® IC- and LPS-treated D1 cells expressed increased
surface levels of all three molecules, indicating effective DC maturation. (C) Subcellular distribution of
MHC class II molecules. D1 cells were incubated for 24 h in the absence (top) or presence of LPS (mid-
dle) or OVA-ICs (bottom). The cells were then fixed, permeabilized, stained, and analyzed by confocal
microscopy. MHC class II molecules were visualized (green) using the mAb Y3P and FITC-conjugated
secondary antibodies, and lysosomal membrane protein Lamp-1 was visualized (red) using the mAb
CD107a and TRITC-conjugated secondary antibody. Yellow, codistribution of the two markers.
 
H-2K
 
b
 
 Transfection of B Lymphomas.
 
IIA1.6 B lymphoma cells
expressing Fc
 
g
 
R-ct
 
g
 
 chimeric receptors (21) were supertrans-
fected with cDNA encoding H-2K
 
b
 
 molecule (28) under the
control of the SR
 
a
 
 promoter. After selection with puromycin,
clones obtained by limited dilution were tested by FACScan
 
®
 
 us-
ing the H-2Kb–specific mAb SF1-1.1. Two independent H-2Kb–
expressing clones were used for MHC class I–restricted antigen
presentation, with similar results.
Results
ICs Induce DC Activation. To analyze the expression
and function of FcgR in murine DCs, we first used a well-
characterized, growth factor–dependent, spleen-derived DC
line called D1 (24). D1 cells display all of the phenotypic
characteristics of immature DCs: low levels of surface MHC
and costimulatory molecules, and abundant endocytic MHC
class II–containing compartments. Upon treatment with LPS
or TNF-a, D1 cells show all of the phenotypical changes
characteristic of DC maturation (24).
We first analyzed the nature of the FcgRs expressed by
D1 cells. Western blot analysis after immunoprecipitation
with the anti-FcgRII and FcgRIII 2.4G2 antibody showed
that D1 cells expressed FcgRIIb1, FcgRIIb2, and FcgRIII
(Fig. 1 A). The two intermediate bands between FcgRIIb1
and FcgRIIb2 most likely represent FcgRIIb19 and an un-
identified spliced variant (29). FcgRI are also expressed in
murine DCs, since mRNA encoding this receptor was
readily detected by reverse transcription PCR (not shown).
These results indicate that murine DCs express FcgRI, II,
and III.
Engagement of FcgRI or III in macrophages triggers cell
activation, causing the production of various cytokines and
chemokines, as well as changes in expression of cell surface
proteins involved in antigen presentation (17, 30). To eval-
uate the ability of ICs to induce DC activation, D1 cells
were incubated for 24 h in the presence of OVA com-
plexed to specific polyclonal anti-OVA IgG antibodies
(OVA-ICs) or LPS, which induces D1 maturation.
As shown in Fig. 1 B, OVA-ICs, like LPS, induced a
marked increase in the surface expression of MHC class II,
CD86, and CD40 molecules (Fig. 1 B), phenotypic
changes characteristic of DC maturation (6, 24). Immuno-
fluorescence and confocal microscopy analysis showed that
both LPS (Fig. 1 C, middle) and OVA-ICs (bottom) also
induced MHC class II redistribution to the plasma mem-
brane (compared with Fig. 1 C, top), as lysosomes became
devoid of MHC class II molecules. Incubation with OVA
alone, or with the antibodies in the absence of OVA, in-
duced no changes in the surface expression of any of the374 FcgR-mediated MHC Class I-restricted Antigen Presentation in Dendritic Cells
markers analyzed or in DC morphology and MHC class II
localization (not shown). Similar results were obtained with
fresh BM-derived DCs (BM-DCs, see below). Like other
maturation stimuli (31, 32), OVA-ICs induced an increase
in MHC class II synthesis and a strong decrease in their rate
of degradation (MHC class II half-life raised from 3–5 to
.40 h; not shown). Therefore, like LPS or TNF-a, FcgR
engagement by ICs induces murine DC maturation in
vitro.
IC Internalization Results in Efficient MHC Class I–restricted
Antigen Presentation. The other main consequence of
FcgR engagement is IC internalization, which induces po-
tent MHC class II–restricted presentation in various cell
types, including DCs (18, 33). However, during cross-
priming, DCs also need to present exogenous antigens on
MHC class I molecules to initiate CTL responses. To de-
termine if ICs may participate in the acquisition of antigens
by DCs for MHC class I–restricted presentation, we next
examined presentation of an OVA-derived peptide to a
CD81 T cell hybrid after FcgR-mediated internalization of
OVA-ICs by murine D1 cells.
As shown previously (34–36), presentation of OVA
257–264/H-2Kb epitope to B3Z T cells (25) after OVA
uptake by fluid phase was only observed at very high, non-
physiological antigen concentrations of 1–10 mg/ml (Fig.
2). In contrast, presentation of the same epitope after inter-
nalization of OVA-ICs was observed at OVA concentra-
tions ranging between 0.1 and 1 mg/ml (Fig. 2), i.e., three
to four orders of magnitude lower antigen concentrations
than uncomplexed OVA. As expected for ICs, the optimal
antigen to antibody ratio was achieved at lower antigen
concentrations as the antibody concentrations decreased
(Fig. 2). The highly efficient OVA presentation observed
after OVA-IC internalization was not due to FcgR engage-
ment per se, since presentation of soluble OVA to B3Z T
cells was not modified by the presence of irrelevant HEL-ICs
(Fig. 2). HEL-ICs induced D1 maturation, as detected by
surface immunostaining of MHC and costimulation mole-
cules (not shown). Therefore, formation of ICs allows effi-
cient acquisition of antigens for peptide presentation to
CTLs on MHC class I molecules.
The capacity of DCs to ingest and process exogenous an-
tigens for presentation by MHC class II molecules is down-
modulated upon DC maturation (37). Therefore, it was
important to determine whether MHC class I–restricted
presentation after IC internalization was also modulated
during DC maturation. Like D1 cells, immature (untreated)
BM-DCs presented OVA epitope 257–264 to B3Z cells
more efficiently after OVA-IC internalization than after un-
complexed OVA uptake (Fig. 3, top left and middle left
panels). In cells treated with LPS for 18 h, presentation after
both OVA-IC and soluble OVA internalization was tran-
siently and reproducibly enhanced (Fig. 3, top center and
Figure 2. MHC class I presentation after IC internalization. (A) D1
cells (5 3 104 cells/well) were incubated at 378C with OVA-ICs, pre-
pared with the indicated concentrations of soluble OVA, and incubated
for 15 min at 378C with 50 (small circles), 25 (medium circles), or 12.5
(large circles) mg/ml of rabbit anti-OVA purified IgGs. In parallel, D1
cells were incubated with soluble OVA (open squares) or soluble OVA
and irrelevant ICs (HEL 30 mg/ml, mAbs anti-HEL, HyHEL5, and
5253C7, at 15 mg/ml each; filled squares). D1 cells were then incubated
for 24 h in the presence of B3Z cells, a T cell hybridoma specific for
OVA-Kb, which carries a b-galactosidase construct driven by NF-AT el-
ements from the IL-2 promoter. T cell activation was measured using a
colorimetric assay for LacZ activity with ONPG as a substrate (one repre-
sentative experiment out of five is shown).
Figure 3. MHC class I–restricted presentation is downmodulated upon
LPS-induced DC maturation. C57BL/6 BM-DCs were cultured in the
absence (left panels) or presence of LPS (20 mg/ml) for 18 h (center pan-
els) or 48 h (right panels), washed, and incubated for an additional 18-h
period with increasing concentrations of OVA-ICs (top panels), soluble
OVA (middle panels), or OVA 257–264 peptide (bottom panels) in the
presence of B3Z cells. One representative experiment out of three is
shown. T cell stimulation was then tested as described above. The effi-
ciency of cross-priming is transiently upregulated and then downmodu-
lated upon DC maturation.375 Regnault et al.
middle center panels). In contrast, MHC class I–restricted
presentation after OVA-IC and soluble OVA internalization
was almost completely abrogated in DCs treated with LPS
for 48 h (Fig. 3, top right and middle right panels). Direct
presentation of the 257–264 OVA peptide was not signifi-
cantly modified by LPS treatment (Fig. 3, bottom panels).
Therefore, as shown previously for MHC class II (31, 32),
MHC class I–restricted presentation of exogenous antigens
is first transiently upregulated and then shut down during
DC maturation. Downregulation of MHC class I–restricted
presentation by DCs upon maturation may prevent presen-
tation of IgG-complexed antigens encountered after DC
migration to secondary lymphoid organs.
MHC Class I Presentation after IC Internalization Is TAP
Dependent and Lactacystin Sensitive. Two pathways for MHC
class I–restricted presentation of exogenous antigens have
been described (11). One reaches the so-called “conven-
tional” pathway after exogenous antigen transfer from en-
docytic compartments to the cytosol. This pathway re-
quires proteasomal degradation, TAP-dependent transport
of the peptides into the lumen of the endoplasmic reticu-
lum, and association to newly synthesized MHC class I
molecules (11). The second pathway is TAP and protea-
some independent; it is inhibited by NH4Cl (which neu-
tralizes lysosomal pH) but not by cycloheximide (CHX; an
inhibitor of protein synthesis), suggesting that the genera-
tion of peptides and their association to MHC class I may
occur in endosomes (11). We next determined which of
these two pathways was used for MHC class I–restricted
presentation after IC internalization.
Antigen presentation by D1 cells after OVA-IC internal-
ization was strongly inhibited by CHX (Fig. 4 A), lactacys-
tin (a specific proteasome inhibitor [38]; Fig. 4 B), and the
peptide aldehyde N-acetyl-Leu-l-Leu-l-norleucinal (LLnL;
Fig. 4 C), which inhibits both lysosomal proteases and the
proteasome (38). Direct presentation of the 257–264 OVA
peptide was not affected by any of these drugs (Fig. 4, A–C).
To assess the specificity of the two protease inhibitors in
DCs, lactacystin and LLnL were tested in parallel on the
MHC class II–restricted presentation after OVA-IC inter-
nalization. Only LLnL, and not lactacystin, blocked MHC
class II–restricted presentation of OVA peptide 323–339 on
I-Ab to BO97.10-specific T cells (Fig. 4 D), indicating that
lactacystin specifically inhibits proteasomal degradation at
the concentrations used. MHC class I–restricted presenta-
tion after OVA-IC internalization was also sensitive to
brefeldin A (which blocks protein transport from the endo-
plasmic reticulum, not shown).
MHC class I–restricted presentation after OVA-IC in-
ternalization also required the TAP1-TAP2 peptide trans-
porter. BM-DCs derived from TAP1-deficient mice did
not present the OVA epitope after internalization of OVA-
ICs, whereas direct presentation of the 257–264 OVA pep-
tide to B3Z T cells was as efficient as with DCs derived
from wild-type (wt) C57BL/6 mice (Fig. 4 E). Therefore,
MHC class I–restricted presentation after IC internalization
reaches the conventional MHC class I presentation pathway.
MHC Class I–restricted Presentation after IC Internalization
Is DC Specific. However, efficient IC internalization is
not restricted to DCs. In B lymphoma cells, we showed
that expression of endocytic FcgRs induces efficient MHC
class II–restricted presentation after IC internalization (20,
39). To determine whether FcgR-mediated MHC class
I–restricted presentation of exogenous antigens is DC spe-
cific, we next examined antigen presentation after OVA-IC
internalization in B lymphoma cells. IIA1.6 B lymphoma
Figure 4. Antigen presentation after IC
internalization reaches the conventional
MHC class I antigen presentation pathway.
(A–C) D1 cells were preincubated alone or
in the presence of CHX (3 mg/ml, A) for
3 h or lactacystin (10 mM, B) or LLnL (8
mM, C) for 1 h. Pretreated D1 cells were
then incubated for an additional 7-h period
with OVA-ICs (0.4 mg/ml of OVA and 20
mg/ml of rabbit anti-OVA IgGs; black bars)
or with the 257–264 synthetic peptide (10
ng/ml; white bars) in the presence of the
same concentrations of inhibitors. D1 cells
were glutaraldehyde fixed before coculture
with B3Z cells. (D) MHC class II–restricted
presentation after OVA-IC internalization
was tested in the presence of lactacystin
(black bars) and LLnL (hatched bars) using
the T cell hybridoma BO97.10 (specific for
OVA 323–339 on I-Ab) on DCs fixed with
glutaraldehyde after antigen pulsing. IL-2
production by BO97.10 was measured with
[3H]thymidine incorporation by IL-2–
dependent CTL.L2 cell line. (E) BM-DCs
were generated as described (reference 33)
from C57BL/6 or TAP-1–deficient mice and were incubated with 257–264 (SIINFKEL) peptide (10 ng/ml; white bars) or with OVA-ICs (0.4 mg/ml
of OVA and 20 mg/ml of anti-OVA rabbit IgGs; black bars) in the presence of B3Z cells for 24 h. Cultures were then treated as described above (one
representative experiment out of three is shown).376 FcgR-mediated MHC Class I-restricted Antigen Presentation in Dendritic Cells
cells are an FcgR clone derived from A20 B lymphoma
cells, one of the cell lines most widely used to analyze
MHC class II–restricted antigen presentation (20, 39). We
have shown previously that IIA1.6 cells expressing recom-
binant FcgRIIb2 or FcgRIII efficiently internalize IC and
strongly promote MHC class II–restricted antigen presenta-
tion (20, 39). In addition, a chimeric receptor composed of
the lumenal and transmembrane domains of FcgRII and
the cytoplasmic tail of the g chain (FcgR-ctg) presents all
of the functional characteristics of FcgRIII in terms of
internalization and antigen presentation (20, 33). I-Ad–
expressing B lymphoma IIA1.6 cells expressing recombi-
nant FcgRIIb2 or FcgR-ctg chimeras were supertrans-
fected with H-2Kb, and compared with D1 cells for MHC
class I and II presentation after OVA-IC internalization.
In FcgR-ctg/H-2Kb–expressing B lymphoma cells,
MHC class II–restricted presentation of the 323–339 OVA
peptide on I-Ad to 54.8 T cell hybridomas was strongly en-
hanced (three to four orders of magnitude) after OVA-IC
internalization (Fig. 5 A). In D1 cells, presentation of the
same peptide on I-Ab to BO97.10 T cell hybridomas was
also enhanced by three to four orders of magnitude after
OVA-IC internalization (Fig. 5 B). Similar results were
obtained with cells expressing FcgRIIb2 (not shown). There-
fore, internalization of ICs results in efficient MHC class
II–restricted presentation in both B lymphoma cells and DCs.
In D1 cells, as shown previously, soluble MHC class
I–restricted presentation was observed after soluble OVA at
high concentrations and after OVA-IC internalization at
low antigen concentrations (Fig. 5 D). In contrast, B lym-
phoma cells expressing FcgR-ctg (Fig. 5 C) or FcgRIIb2
(not shown) were completely incompetent for MHC class
I–restricted presentation of OVA-derived peptide 257–
264, after internalization of OVA-ICs or uncomplexed
OVA at high concentrations. In contrast, when incubated
with the OVA 257–264 synthetic peptide, both D1 cells
and B lymphoma cells activated B3Z cells (Fig. 5, C and D).
Like B lymphoma cells, IFN-g–treated peritoneal macro-
phages were capable of directly presenting OVA peptide 257–
264 to B3Z cells, but not after OVA-IC or uncomplexed
OVA internalization (not shown). Therefore, in contrast to
MHC class II–restricted presentation, the FcgR-mediated
pathway for presentation of exogenous antigens by MHC
class I molecules is restricted to DCs.
Role of the FcR-associated g Chain in IC-induced DC Matu-
ration and MHC Class I–restricted Antigen Presentation. The
results presented thus far suggest that FcgRs are involved in
both the induction of DC maturation and antigen uptake
for efficient MHC class I–restricted presentation of exoge-
nous antigens. Importantly, FcgRI and FcgRIII trigger cell
activation in a variety of cell types through an ITAM found
in the associated g chain (17). To determine the nature of
the FcgRs involved in the triggering of DC maturation by
ICs, we prepared BM-DCs from wt mice and from mice
deficient for the FcgRI- and FcgRIII-associated g chain
(22). Surface expression of FcgRII and III (as detected by
the mAb 2.4G2) was decreased but not abolished in BM-
DCs from the g chain2/2 mice (Fig. 6 A), confirming that
Figure 5. MHC class I–restricted presentation after OVA-IC internalization is DC specific. D1 cells were tested concurrently with a B cell line ex-
pressing recombinant internalization-competent FcgR-ctg chimeric receptors and supertransfected with cDNA encoding the Kb MHC class I molecule.
B lymphoma cells (A and C) and D1 cells (B and D) were incubated with the indicated concentrations of OVA (squares) or OVA complexed to 20 mg/
ml of anti-OVA rabbit polyclonal IgG (OVA-IC; circles). D1 cells were fixed with glutaraldehyde before coculture with T cells. MHC class II–restricted
presentation of OVA was tested using the T cell hybridomas BO97.10 (for I-Ab on D1 cells; B) or 54.8 (for I-Ad on B lymphoma cells; A), which both
recognize the 323–339 epitope, in association with I-Ab and I-Ad, respectively. MHC class I presentation by B lymphoma cells (C) or D1 cells (D) was
tested using B3Z T cell hybridoma as described in the legend to Fig. 2. The 323–339 and 257–264 synthetic peptides (10 mg/ml) were used as positive
controls (histograms).377 Regnault et al.
BM-DCs from the g chain2/2 mice still express FcgRII
and suggesting that BM-DCs from wt C57BL/6 mice ex-
pressed both FcgRII and III.
To determine the requirement for g chain in DC activa-
tion, the ability of LPS and OVA-ICs to induce maturation
was analyzed. LPS induced a marked increase of the surface
expression of MHC class II, CD86, and CD40 molecules
on DCs from wt and g chain2/2 mice (Fig. 6 B), as well as
all of the morphological modifications characteristic of DC
maturation (not shown). In contrast, OVA-ICs did not in-
duce any detectable maturation in BM-DCs from g2/2
mice, whereas they induced maturation of BM-DCs from
wt mice (Fig. 6 B). Therefore, DCs from g chain2/2 mice
presented a selective defect in IC-induced maturation.
The involvement of the g chain in MHC class I–restricted
presentation was tested next. As expected, BM-DCs from
both wt and g chain2/2 mice presented soluble OVA and
the 257–264 OVA peptide to the B3Z T cell hybridomas
with similar efficiencies (Fig. 7). BM-DCs from wt mice
also presented the OVA epitope after OVA-IC internaliza-
tion at low antigen concentrations (Fig. 7). In contrast,
DCs from g2/2 mice did not show any significant MHC
class I–restricted presentation after incubation with OVA-ICs
(Fig. 7). These DCs had also lost the ability to present
OVA peptide 323–339 in association to I-Ab MHC class II
molecules (not shown). In addition, FcgR-mediated IC
internalization in BM-DCs from g chain2/2 mice was de-
creased, as measured both biochemically and by immu-
nofluorescence and confocal microscopy (not shown),
suggesting that the absence of antigen presentation by
BM-DCs from g chain2/2 mice results from inefficient IC
internalization.
Therefore, the FcgR-associated g chain is required for
both induction of DC maturation by ICs and promotion of
MHC class I–restricted presentation, indicating that FcgRI
and/or FcgRIII (the two g chain–associated FcgRs) are re-
quired for the functions of ICs in DCs.
Discussion
Our results evidence a novel receptor-mediated pathway
for antigen acquisition for MHC class I–restricted presenta-
tion. This FcgR-mediated cross-priming pathway is DC
specific and is inactive in mature DCs. It requires the
TAP1-TAP2 transporter and is sensitive to lactacystin, a
proteasome inhibitor, indicating that after internalization,
IgG-complexed antigens are transferred into the cytosol
and reach the conventional MHC class I antigen presenta-
Figure 6. The g subunit of FcgRs is required for IC-induced DC maturation. (A) 2.4G2 staining in BM-DCs from wt C57BL/6 or g chain2/2 mice.
BM-DCs from wt and g chain2/2 mice were stained for FcgRII and III with 2.4G2 mAb before analysis by FACscan®. BM-DCs from wt mice showed
stronger surface staining with 2.4G2 than BM-DCs from g chain2/2 mice, suggesting that BM-DCs from wt C57BL/6 mice expressed both FcgRII and
III. (B) BM-DCs from g chain2/2 mice are not activated by ICs. BM-DCs from wt and g chain2/2 mice were incubated for 24 h alone (dotted line) or
in the presence of LPS (solid line) or OVA-ICs (0.4 mg/ml of OVA and 20 mg/ml of rabbit anti-OVA IgGs; bold line) and stained for MHC class II
(Y3P), CD40 (HM40-3), and CD86/B7.2 (GL1) before analysis by FACscan®. BM-DCs from wt mice were activated by both LPS and ICs. In contrast
to LPS, OVA-ICs did not induce effective DC maturation in g chain2/2 mice.
Figure 7. BM-DCs derived from g chain2/2 mice fail to present pep-
tides derived from OVA-ICs on MHC class I molecules. C57BL/6 (open
symbols) or g chain2/2 BM-DCs (filled symbols) were incubated in the
presence of the indicated concentrations of soluble OVA (squares), OVA-
ICs (20 mg/ml rabbit IgG anti-OVA; circles), or 257–264 peptide (trian-
gles) for 18 h in the presence of B3Z T cells. Antigen presentation was
quantified as described above. One representative of three experiments is
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tion pathway. FcgR engagement also induces full DC acti-
vation, reflected by increased levels of MHC and costimu-
latory molecules (CD40, CD80, and CD86) at the cell
surface. Simultaneous induction of maturation and MHC
class I and class II–restricted presentation by a single recep-
tor–ligand interaction should result in efficient T cell prim-
ing in vivo.
This pathway is not the first described for cross-priming
in vitro. Fluid phase internalization can result in MHC class
I–restricted presentation, but only at very high antigen
concentrations (3–10 mg/ml in the OVA system), in both
macrophages and DCs (34, 36). Interestingly, induction of
macropinocytosis was shown to result in cross-priming in
vitro (35). In addition, phagocytosis somehow favors MHC
class I–restricted presentation of exogenous antigens in
macrophages and DCs. Indeed, internalization of bacteria
by macrophages or DCs (12, 14, 15) and phagocytosis of
apoptotic bodies by DCs (4) also result in cross-priming.
Likewise, antigen coupling to (12), or in some case mixing
with (13), synthetic beads forces antigen phagocytosis and
remarkably increases the efficiency of MHC class I antigen
presentation (peptides derived from OVA may then be pre-
sented at 1–3 mg OVA/ml). Thus, the mode of antigen in-
ternalization influences cross-priming in vitro.
The mode of IC internalization (endocytosis or phago-
cytosis) in DCs is still unclear. However, our results exclude
the possibility that the efficient cross-priming observed with
ICs is due to FcgR-independent phagocytosis. Indeed, in
DCs from g chain2/2 mice, MHC class I–restricted presen-
tation was not observed, demonstrating that the DCs (and the
FcgRs they express) and not the eventual particulate form of
the antigen are determinant for cross-priming with ICs.
FcgR-mediated cross-priming is TAP dependent and
sensitive to the proteasome inhibitor lactacystin, suggesting
that IgG-complexed antigens are transferred from en-
docytic compartments into the cytosol. Although the
mechanism of this transfer is still unclear, it was shown pre-
viously that macropinocytosis results in increased antigen
delivery to the cytosol (40). After IC internalization at low
antigen concentrations, we observed antigen transfer to the
cytosol by immunofluorescence and confocal microscopy
(Rodriguez, A., unpublished results). However, the effi-
cient cross-priming observed in DCs after IC internaliza-
tion was not due to an overall effect of FcgR engagement,
since simultaneous engagement of FcgRs by irrelevant ICs
did not increase the efficiency of cross-priming with solu-
ble OVA internalized by fluid phase (Fig. 2) or its transfer
to the cytosol (not shown). This observation also suggests
that, to be transferred into the cytosol after internalization,
antigens need to be targeted by FcgRs to a particular pop-
ulation of endosomes or lysosomes.
In contrast, IC internalization in other cell types express-
ing endocytosis-competent FcgRs, like macrophages or
transfected B lymphoma cells, did not result in MHC class
I–restricted presentation. The molecular bases of this DC
specificity are still unclear. They are certainly not related to
the ability of FcgRs to mediate IC internalization or cell
activation, which are both efficient in macrophages or
transfected B lymphoma cells. In contrast, we found that
antigen transfer to the cytosol is inefficient in these two cell
types compared with DCs (Rodriguez, A., unpublished re-
sults). Therefore, the specificity of DCs for cross-priming
might be related to a selective ability of DCs to deliver an-
tigen from endosomes or lysosomes into the cytosol.
The other major effect of FcgR engagement in DCs is
induction of maturation. Indeed, all of the phenotypical,
morphological, and functional modifications caused by in-
flammatory cytokines or LPS were also induced by ICs. In
addition, none of these modifications were observed with
DCs from g chain2/2 mice, demonstrating the implication
of the g chain in the induction of DC maturation by ICs.
We found here that mouse D1 cells (as well as BM-DCs)
express the two g chain–dependent FcgRs, FcgRI (CD64)
and FcgRIII (CD16). It is not clear to date which of these
two receptors is required for DC maturation, but it will be
directly addressed using FcgRI and/or FcgRIII2/2 mice.
Whether FcgRI or FcgRIII is used, the involvement of
the FcgR-associated g chain in DC maturation indicates
that an ITAM-bearing receptor triggers DC activation.
FcgR cross-linking causes activation of protein tyrosine ki-
nases (PTKs) from the src family (17). These PTKs phos-
phorylate tyrosine residues in the ITAM, thus inducing as-
sociation to syk PTK, leading to Ca21 release from
intracellular stocks and to a wide variety of biological re-
sponses. Our observation represents the first evidence of
induction of DC activation and maturation through an
ITAM-containing receptor. Interestingly, the g chain ITAM
also bears an internalization signal that mediates endocytosis
of FcgRIII (20), and more recently, we showed that the
ITAM also determines g chain–mediated transport from
endosomes to lysosomes (41). Thus, FcgRs may initiate
DC maturation and simultaneously target antigen to the
appropriate endocytic compartment, where peptides are
loaded onto MHC class II and from where antigens are
transferred into the cytosol.
Indeed, CD41 T cells play an important role in antiin-
fectious CD81 T cell–mediated responses, even if they are
dispensable in some of them (42–44). The antigen presen-
tation on both MHC class I and class II molecules that we
observed after IC internalization by DCs would ensure an
optimal stimulation of both CD41 and CD81 T cells. At
the end of primary responses and in the course of secondary
immune responses, the production of specific antibodies
induces formation of complexes between antigens derived
from infected cells or tumor cells and specific IgGs. These
complexes could be taken up by FcgRs on DCs. After in-
ternalizing ICs, DCs would then present the antigen to
specific CD4 T cells, which activate them through interac-
tions implicating costimulatory molecules like CD40-
CD40L and convert them into DCs capable of priming
CD81 T cells (7–10). However, since FcgR engagement
also induces efficient maturation, IC-activated DCs could
potentially prime CD81 T cells directly, bypassing cognate
CD41 T cell help. This mechanism could operate in cer-
tain antiviral and/or antitumoral immune responses. How-
ever, it could also induce inappropriate CTL responses,379 Regnault et al.
since the absence of CD41 T cells would not allow a con-
trol of specificity, i.e., a “double check.”
In what physiological situation might ICs trigger CTL
responses? Specific antibodies, which may potentially form
ICs, are produced during most immune responses, includ-
ing those where the final effectors are CTLs. ICs may par-
ticipate in DC-mediated CD81 T cell priming in the case
of secondary immune responses, when specific IgGs may
be produced very rapidly. In the case of ongoing immune
responses, which in many cases correspond to situations of
immunosuppression, such as chronic infections or tumors,
cross-priming through ICs may contribute to the establish-
ment of specific tolerance. ICs have also been reported to
play critical roles in several autoimmune diseases. Amplifi-
cation of anti-self CTL responses by DCs that have ac-
quired autoantigens from ICs may contribute to the trig-
gering or development of autoimmune pathologies.
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